MDxHealth SA (Euronext: MDXH.BR) today announces that positive data from a pre-biopsy clinical validation and optimization study of SelectMDx® were presented at the 34th Annual European Association of Urology (EAU) conference in Barcelona, Spain, March 15-19 2019.
This pan-European multicenter clinical study was designed to optimize and validate SelectMDx in assessing the risk of high-grade prostate cancer (PCa) in men with elevated prostate specific antigen levels (PSA). Data from the study showed that SelectMDx accurately predicts both low-risk as well as aggressive prostate cancer across all patient groups.
“This retrospective clinical validation study clearly confirms the value of the test to guide urologists to identify men at risk for aggressive disease, who may benefit from a biopsy or mpMRi procedure,” said Dr. Jack Schalken, Professor of Experimental Urology at the Radboud Medical Center in Nijmegen, The Netherlands. “The performance of SelectMDx in this multicenter study confirms previous published data for the intended use of the test.”
